top of page
PRESERVING LONG-TERM KIDNEY HEALTH
Oxalo Therapeutics is developing first-in-class therapeutics to treat rare renal diseases and prevent recurrent kidney stones
starting with an orphan disease
Primary hyperoxaluria is a monogenic autosomal recessive liver disease that results in excessive endogenous oxalate.
Extreme levels of oxalate lead to recurrent kidney stone formation, nephrocalcinosis and end stage renal disease very early in life.
There are currently no effective therapies for this ultra rare disease, which affects an estimated 5,000 patients in the U.S. and E.U.
Oxalo Therapeutics is tackling primary hyperoxaluria and other oxalate pathologies
The gut microbe Oxalobacter formigenes works together with the large intestine to maintain oxalate homeostasis.
Oxalo Therapeutics is isolating this powerful mechanism and replicating it through a first-in-class peptide therapeutic.
At Oxalo, we are committed to developing innovative therapies for patients with severe and rare kidney diseases caused by oxalate.
Oxalo Therapeutics, Inc.
1452 E. 53rd St, 2nd Floor
Chicago, IL 60615
bottom of page